Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0061)
Name
Hesperidin
Synonyms
hesperidin; Cirantin; 520-26-3; Hesperidoside; Hesper bitabs; Hesperetin 7-rhamnoglucoside; Hesperetin 7-rutinoside; Hesperetin-rutinosid; Hesperidine; Ciratin; (S)-(-)-Hesperidin; Hesperetin 7-O-rutinoside; NSC 44184; CCRIS 3940; EINECS 208-288-1; (2S)-Hesperidin; UNII-E750O06Y6O; BRN 0075140; DIOSVEIN; Hesperetin-7-O-rhamnoglucoside; Hesperidin, (2S)-; DTXSID9044328; Hesperetin-7-rutinoside; CHEBI:28775; E750O06Y6O; USAF CF-3; Hesperitin-7-rhamnoglucoside; Hesperidin, (S)-(-)-; 3',5'-Dihydroxy-4'-methoxy-7-rutinosyloxyflavan-4-on; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; DTXCID7024328; EC 208-288-1; 5-18-05-00218 (Beilstein Handbook Reference); Hesperidin (JAN); Hesperetin, 7-(6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside); C28H34O15; NSC-44184; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one; (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)chroman-4-one; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydo-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; 5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((6-O-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyl)oxy)-4-chromanon; 7-((6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one, (S)-; 7-(6-O-Desoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyloxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-chromanon; SMR000718775; HESPERIDIN [JAN]; MFCD00075663; HESPERIDIN (MART.); HESPERIDIN [MART.]; HESPERIDIN (USP-RS); HESPERIDIN [USP-RS]; (s)-7-[[6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one; Aurantiamarin (Methyl Hesperidin); 3',5'-DIHYDROXY-4'-METHOXY-7-RUTINOSYLOXYFLAVAN-4-ONE; hesperetin 7-(6-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside; NSC44184; Hesperidin 2S; 2S, Hesperidin; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chroman-4-one; Hesperitin-7-rutinoside; Hesperetin 7 Rutinoside; SR-01000799145; Hesperetin 7 Rhamnoglucoside; Hesperidina; 7-Rhamnoglucoside, Hesperetin; Hesperidin,(S); NCGC00016481-01; (2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one (Hesperidin); (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)chroman-4-one; CAS-520-26-3; Hesperetin Glycoside; Hesperidin, >=80%; HESPERIDIN [MI]; DIOSMIN [NDI]; Prestwick3_000400; HESPERIDIN [INCI]; HESPERIDIN [VANDF]; Glucopyranoside, hesperetin-7 6-O-(6-deoxy-alpha-L-mannopyranosyl)-, beta-D-; HESPERIDIN [WHO-DD]; SCHEMBL94586; BSPBio_000619; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; cid_10621; Hesperidin, analytical standard; BPBio1_000681; CHEMBL449317; NDI 590 [FDMS]; BCBcMAP01_000136; BDBM61776; NDI 590; 2H-pyran-2-yloxy)chroman-4-one; QUQPHWDTPGMPEX-QJBIFVCTSA-N; HMS2096O21; HMS2233I03; HMS3713O21; Tox21_110448; s2309; AKOS015895450; CCG-208580; CS-5631; DB04703; KS-5308; SMP1_000149; NCGC00179501-01; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-; HY-15337; AB00513829; H0049; C09755; D01038; (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-; EN300-7419024; Q385937; Hesperidin, primary pharmaceutical reference standard; methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-; SR-01000799145-4; SR-01000799145-5; SR-01000799145-7; 7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-; BRD-K38903228-001-02-8; BRD-K38903228-001-13-5; Hesperidin, European Pharmacopoeia (EP) Reference Standard; Hesperidin, Pharmaceutical Secondary Standard; Certified Reference Material; Flavanone, 3',5,7-trihydroxy-4'-methoxy-, 7-(6-O-alpha-L-rhamnosyl-D-glucoside); (2S)-2-(4-methoxy-3-oxidanyl-phenyl)-7-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5R,6S)-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxymethyl]-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-oxidanyl-2,3-dihydrochromen-4-one; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-2-oxanyl]oxymethyl]-2-oxanyl]oxy]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDRO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; (2S)-7-((6-O-(6-DEOXY-alpha-L-MANNOPYRANOSYL)-beta-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDRO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; (S)-7-[[6-O-(6-Deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)-; 5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-7-((6-O-.ALPHA.-L-RHAMNOPYRANOSYL-.BETA.-D-GLUCOPYRANOSYL)OXY)-4-CHROMANON

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C28H34O15
IUPAC Name
(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
Canonical SMILES
CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
InChI
InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
InChIKey
QUQPHWDTPGMPEX-QJBIFVCTSA-N
PubChem CID
10621
TTD Drug ID
D0I9HF
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Intervertebral disc degeneration ICD-11: FA80
 Disease Info 
Responsed Regulator Transcription factor p65 (RELA) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
In Vivo Model
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.

    Click to Show/Hide
Response regulation The current study proved for the first time that Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-kB pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Intervertebral disc degeneration ICD-11: FA80
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
In Vivo Model
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.

    Click to Show/Hide
Response regulation Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-B pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration.
References
Ref 1 Hesperidin mitigates oxidative stress-induced ferroptosis in nucleus pulposus cells via Nrf2/NF-B axis to protect intervertebral disc from degeneration. Cell Cycle. 2023 May;22(10):1196-1214. doi: 10.1080/15384101.2023.2200291. Epub 2023 Apr 13.